Endocrine Abstracts

Maturity-onset diabetes of young 5 (MODY5) is a type of monogenic diabetes involving multiple organs including pancreas and kidneys. This is caused by mutation/deletion of the hepatocyte nuclear factor-1β (HNF-1β) gene located in the chromosome region 17q12.We report a 10-year-old, non-obese girl who was diagnosed with diabetes with features of insulin resistance. She was found to have a heterozygous whole gene deletion of HNF-1&#9...

Introduction: One third of children in the UK are overweight or obese. The Obesity Services for Children and Adolescents (OSCA) group have agreed upon a guideline for paediatricians on the assessment and management of obese children.Audit aim: To evaluate and improve the care of obese and overweight children.Method: Obese patients seen in secondary care were retrospectively audited from 2008 to 2014.Results: ...

Objectives: The use of CSII in very young diabetic children was initially limited. The criteria for continued use are better long term glycaemic control and reduced hypoglycaemia episodes. The objective of this study was to evaluate the benefits of CSII on glycaemic control, acute complications and quality of life of diabetic patients.Methods: Retrospective analyses of data from patients with type 1 diabetes from our database that were started on CSII fr...

Background: Obese young people are likely to suffer significant morbidity in adult life. Successful intervention during adolescence may have far-reaching benefits. Evidence is emerging that patient-responsive clinical services may deliver improved outcomes.Aims: To assess the perceptions of obese young people about weight and weight-management services.Method: Annonymised, postal questionnaire survey of 116 obese young people (9&#1...

Background: Childhood obesity is increasingly associated with type 2 diabetes (T2D). Metformin reduces the risk for T2D in adult obese non-diabetic patients, but the evidence in obese children and young people (CYP) is inconclusive.Design: The metformin in obese children and adolescents (MOCA) trial was a prospective, multi-centre, randomized, double-blind, placebo-controlled trial of 1.5 g metformin daily in CYP with raised fasting or post-prandial insu...

Background and objective: Childhood obesity is associated with reduced insulin sensitivity and increased risk for type 2 diabetes (T2D). The objective of the MOCA trial was to investigate the effect of metformin in severely obese children and adolescents.Design and Methods: In a six month multi-centre randomized, double-blind placebo-controlled trial metformin (1.5 g daily) or placebo was given to children and adolescents (8–18 years) with insulin r...